Micro Pharmaceuticals

Zim Laboratories Ltd.

ZIMLAB

₹102.05

13.91% (12.46)

Market Cap

₹495 Cr.

P/E

40.71

Zim Laboratories Ltd.

Price
Growth Table
Balance Sheet
Profit & Loss
Cash Flow
Cash Flow Analysis
Ratios
Quarterly Results
Reverse DCF

FAQs on Zim Laboratories Ltd. Shareprice

Has the share price of Zim Laboratories grown faster than its competition?

Zim Laboratories has given lower returns compared to its competitors.
Zim Laboratories has grown at ~15.52% over the last 6yrs while peers have grown at a median rate of 16.54%

Is Zim Laboratories stock expensive?

Yes, Zim Laboratories is expensive.
Latest PE of Zim Laboratories is 37.17, while 3 year average PE is 27.73.
Also latest EV/EBITDA of Zim Laboratories is 12.54 while 3yr average is 10.69.

View FAQ's On Business

Growth Table

Zim Laboratories Ltd.
Brooks Laboratories
Loading...
Medico Remedies
Loading...

In %	1yr	2yr	3yr	4yr	5yr	6yr	7yr	8yr	9yr	10yr
Share Price CAGR	7.33	-4.07	9.71	36.70	35.02	17.84	—	—	—	—
TTM EPS CAGR	-28.56	-29.10	-6.48	13.37	29.52	—	—	—	—	—
Sales CAGR	3.16	-2.48	4.37	5.39	6.42	2.06	4.73	14.44	—	—
PAT Margin (Abs Growth)	-1.57	-3.00	-1.24	0.74	1.94	-1.45	-3.84	-4.59	1.28	10.98
PE CAGR	20.27	28.86	11.96	16.42	1.09	—	—	—	—	—
CFO CAGR	211	15.14	0.94	12.27	18.22	6.37	4.71	5.87	9.73	24.66

* Share price and PE growth are updated everyday. All other fields are as of latest financial year end. EPS adjusted for bonus and splits.

Balance Sheet

Zim Laboratories Ltd.
Brooks Laboratories
Loading...
Medico Remedies
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Assets	257	250	295	328	320	322	343	342	447	472
Non Current Assets	102	105	125	134	143	133	129	146	209	241
Net Block	92.19	88.75	94.16	106	116	107	106	109	161	164
Capital Work in Progress	2.93	3.82	8.29	13.32	9.62	10.68	11.74	26.99	42.28	44.05
Intangible Assets Under Development	—	1.12	3.52	5.56	4.88	6.12	6.65	9.15	18.77	26.41
Long Term Investments	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05
Current Assets	155	154	173	195	182	192	214	191	228	231
Inventory	37.72	35.47	51.56	55.05	56.39	54.35	75.28	53.71	81.26	86.47
Accounts Receivable	88.53	88.18	89.22	93.10	67.93	72.25	89.52	95.25	100	107
Short Term Investments	—	—	—	—	—	—	—	—	—	—
Cash & Bank Balances	6.39	5.61	3.53	2.94	3.95	8.35	4.97	7.52	10.46	2.49
Liabilities	257	250	295	328	320	322	343	342	447	472
Shareholders Funds	98.96	118	137	151	154	161	176	200	239	252
Share Capital	8.00	8.03	8.06	16.12	16.18	16.24	16.24	48.73	48.73	48.73
Reserves	90.34	110	128	134	137	145	159	152	190	204
Non Current Liabilities	34.75	18.09	16.61	20.19	22.72	19.40	20.01	30.45	48.65	53.42
Secured Loans	33.98	26.75	15.91	19.14	27.01	21.83	18.92	24.62	35.60	—
Unsecured Loans	0.77	0.77	4.37	3.02	0.41	—	—	—	—	40.30
Current Liabilities	124	113	141	156	143	142	147	111	159	166
Accounts Payable	46.97	45.05	66.26	71.95	66.00	64.87	81.07	58.24	62.38	69.51
Short Term Loans	56.30	46.70	49.56	40.15	49.69	44.60	17.34	22.88	55.04	71.86

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

Increase
Decrease
Total

No data available.

*Data is as of latest FY end

Profit & Loss

Zim Laboratories Ltd.
Brooks Laboratories
Loading...
Medico Remedies
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Sales	269	235	273	335	278	307	333	399	367	379
Operating Expenses	239	204	238	293	255	268	292	347	326	335
Raw Material	156	119	142	160	150	160	170	182	185	155
Material Cost (%)	58.74	51.05	51.65	47.56	51.54	51.63	48.09	49.89	46.66	41.23
Employee Cost	30.70	33.00	40.80	48.26	35.35	35.76	40.07	49.32	53.34	60.76
Power & Fuel Cost	6.40	5.35	5.75	7.19	7.47	7.04	9.14	11.09	13.47	—
Operating Profit	29.20	31.49	34.78	42.03	22.61	39.76	40.98	51.99	41.33	43.73
Other Income	3.91	5.51	3.42	2.05	4.52	2.34	4.40	6.41	5.18	5.79
OPM (%)	10.87	13.40	12.75	12.53	8.14	12.94	12.29	13.04	11.25	11.54
Depreciation and Amortisation	8.76	9.02	9.79	11.42	14.41	15.79	16.03	17.47	15.95	20.11
Interest	13.65	10.47	9.34	10.59	12.65	10.90	8.31	5.58	6.92	11.39
Profit Before Tax	5.36	17.50	24.94	22.07	0.07	10.23	21.04	35.35	23.64	18.01
Tax	0.26	-1.09	5.83	6.73	-3.23	2.91	6.49	10.92	6.40	5.84
Net Profit	5.10	18.59	19.11	15.34	3.30	7.32	14.55	24.43	17.25	12.16
Number of shares(Crs)	—	—	—	1.61	1.62	1.62	1.62	4.87	4.87	—
Dividend Payout Ratio(%)	15.69	2.16	2.11	5.25	0.00	0.00	0.00	0.00	0.00	—

TTM Values as of Mar 2025

Cash Flow

Zim Laboratories Ltd.
Brooks Laboratories
Loading...
Medico Remedies
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash from Operating Activity	21.94	32.07	36.68	34.94	21.92	31.85	49.21	38.17	16.28	41.15
Profit Before Tax	5.36	17.50	24.94	22.07	0.07	15.41	21.04	35.35	23.64	18.01
Adjustments	29.04	20.78	12.84	23.82	26.25	25.79	22.01	22.16	22.01	32.43
OCF Before Working Capital	34.41	38.28	37.78	45.89	26.32	41.20	43.05	57.51	45.65	50.44
Working Capital Changes	-11.32	-3.72	2.96	-9.64	0.56	-8.24	6.58	-12.19	-26.79	-10.36
Taxes Paid	-1.14	-2.49	-4.06	-1.31	-4.96	-1.11	-0.43	-7.15	-2.58	1.08
Cash from Investing Activity	-11.73	-7.24	-25.83	-20.68	-19.41	-5.88	-14.57	-36.20	-73.01	-39.93
Net Fixed Assets Purchased	-13.11	-8.52	-28.49	-20.30	-18.54	-6.47	-15.07	-36.65	-73.38	-40.07
Fixed Assets Purchased	-13.16	-8.88	-28.52	-20.37	-18.58	-6.48	-15.23	-36.67	-73.92	-40.80
Fixed Assets Sold	0.05	0.35	0.03	0.07	0.04	0.01	0.16	0.02	0.55	0.73
Investment Purchased	-3.07	-2.39	-1.26	-1.02	-0.68	—	—	—	-0.28	—
Investment Sold	3.98	3.23	3.69	0.48	1.61	0.20	0.30	0.36	0.60	—
Interest Recieved	0.46	0.43	0.22	0.15	0.14	0.39	0.19	0.08	0.04	0.05
Dividends Recieved	0.01	0.01	0.01	0.01	0.01	—	0.01	0.01	0.01	0.01
Subsidiary Investments	—	—	—	—	—	—	—	—	—	—
Cash from Financing Activity	-10.35	-25.15	-9.80	-15.16	-2.16	-25.97	-32.97	0.55	59.53	-9.11
Proceeds From Shares	—	0.03	0.03	—	0.06	0.06	—	—	—	—
Net Long Term Borrowings	-3.77	-4.84	-2.53	5.16	3.59	-4.33	-2.86	2.88	15.21	9.30
Proceeds From Borrowings	0.10	0.15	4.95	17.16	35.00	19.17	27.07	18.35	28.15	24.62
Repayment From Borrowings	-3.87	-4.99	-7.48	-12.00	-31.41	-23.49	-29.93	-15.47	-12.93	-15.32
Interest Paid	-11.59	-9.95	-9.13	-10.11	-13.65	-10.27	-7.93	-5.53	-7.51	-12.30
Dividend Paid	—	-0.73	-0.74	-0.77	-0.74	-0.02	-0.17	-0.06	-0.05	-0.06
Net Cash Flow	-0.14	-0.32	1.04	-0.90	0.35	-0.00	1.66	2.51	2.80	-7.88
Opening Cash & Cash Equivalents	0.88	0.74	0.42	1.47	0.50	1.46	1.39	3.42	6.42	9.60
Effect of FX	—	—	—	-0.07	0.61	-0.06	0.36	0.49	0.38	0.22
Closing Cash & Cash Equivalents	0.74	0.42	1.47	0.50	1.46	1.39	3.42	6.42	9.60	1.95
Net Capex (est)	13.11	8.52	28.49	20.30	18.54	6.47	15.07	36.65	73.38	40.07
Free Cash Flow (est)	8.83	23.55	8.19	14.63	3.37	25.38	34.14	1.52	-57.10	1.09

Cash Flow Analysis

Increase
Decrease
Total

No data available.

Ratios

= Dominant Factor

Zim Laboratories Ltd.
Brooks Laboratories
Loading...
Medico Remedies
Loading...

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Operational Ratios
Quick Ratio	0.92	0.96	1.05	0.87	0.90	0.88	0.97	0.94	1.24	0.92
Liquid Assets (Crs)	123	119	118	123	140	126	137	138	137	146
Current Liabilities (Crs)	134	124	113	141	156	143	142	147	111	159
Current Ratio	1.26	1.26	1.36	1.22	1.25	1.27	1.35	1.45	1.72	1.43
Current Assets (Crs)	169	155	154	173	195	182	192	214	191	228
Current Liabilities (Crs)	134	124	113	141	156	143	142	147	111	159
Interest Coverage Ratio	-1.58	1.39	2.67	3.67	3.08	1.01	1.94	3.53	7.34	4.41
EBIT (Crs)	16.74	24.35	27.97	28.42	32.66	12.72	26.31	29.35	40.93	30.57
Interest Expenses (Crs)	10.32	13.65	10.47	9.34	10.59	12.65	10.90	8.31	5.58	6.92
Fixed Asset Turnover	2.48	2.23	2.40	2.42	2.47	1.74	1.86	1.85	2.01	1.38
Net Sales (Crs)	266	269	235	273	335	278	307	333	399	367
Fixed Assets (Crs)	108	120	97.77	113	136	159	165	180	199	267
Cash Conversion Cycle	40.09	38.79	49.29	31.77	-0.91	3.15	-1.53	-6.61	15.82	35.70
Inventory Days	61.16	55.29	55.43	57.91	58.02	73.23	65.77	70.95	59.07	67.04
Days Receivable	108	112	134	118	99.21	106	83.26	88.55	84.61	97.06
Days Payable	129	129	140	144	158	176	151	166	128	128
Debt to Equity Ratio	0.99	0.97	0.68	0.59	0.51	0.58	0.50	0.29	0.30	0.44
Total Debt (Crs)	93.00	95.97	80.56	81.15	77.20	89.85	81.07	51.18	59.41	106
Shareholders Equity (Crs)	94.21	98.96	118	137	151	154	161	176	200	239
Free Cash Flow/Sales (%)	-3.50	3.29	10.02	3.00	4.36	1.21	8.26	10.24	0.38	-15.54
Free Cash Flow(est) (Crs)	-9.33	8.83	23.55	8.19	14.63	3.37	25.38	34.14	1.52	-57.10
Net Sales (Crs)	266	269	235	273	335	278	307	333	399	367
Profitability Ratios
Gross Margin (%)	31.85	41.26	48.95	48.35	52.44	48.46	48.37	51.91	50.11	53.34
Op Profit Margin (%)	8.03	10.87	13.40	12.75	12.53	8.14	12.94	12.29	13.04	11.25
Operating Profit (Crs)	23.87	33.10	36.99	38.21	44.08	27.13	42.10	45.38	58.40	46.52
Net Sales (Crs)	266	269	235	273	335	278	307	333	399	367
Net Profit Margin (%)	-8.11	1.90	7.91	7.01	4.57	1.19	2.38	4.36	6.13	4.69
Net Profit (Crs)	-21.61	5.10	18.59	19.11	15.34	3.30	7.32	14.55	24.43	17.25
Net Sales (Crs)	266	269	235	273	335	278	307	333	399	367
ROCE (%)	12.70	18.21	20.50	18.55	19.07	7.21	14.60	15.00	17.73	10.64
EBIT (Crs)	16.74	24.35	27.97	28.42	32.66	12.72	26.31	29.35	40.93	30.57
Capital Employed (Crs)	132	134	136	153	171	177	180	196	231	287
Return on Assets (%)	-8.12	1.98	7.45	6.49	4.68	1.03	2.27	4.24	7.15	3.86
Net Profit (Crs)	-21.61	5.10	18.59	19.11	15.34	3.30	7.32	14.55	24.43	17.25
Total Assets (Crs)	266	257	250	295	328	320	322	343	342	447
ROIC (%)	9.62	16.07	18.69	14.56	13.59	243	10.69	9.64	11.42	7.09
Op Profit after Taxes (Crs)	11.58	19.43	23.86	19.15	21.28	394	17.15	17.25	23.86	18.52
Invested Capital (Crs)	120	121	128	132	157	162	160	179	209	261
ROE (%)	-22.94	5.15	15.71	13.99	10.15	2.14	4.55	8.28	12.20	7.22
Net Profit Margin (%)	-8.11	1.90	7.91	7.01	4.57	1.19	2.38	4.36	6.13	4.69
Asset Turnover ratio	1.00	1.04	0.94	0.93	1.02	0.87	0.95	0.97	1.17	0.82
Equity Multiplier	2.83	2.60	2.11	2.16	2.17	2.08	2.00	1.95	1.70	1.87
Adjusted EPS	-4.50	1.06	3.86	3.95	3.17	0.68	1.50	2.99	5.01	3.54
Valuation Ratios
P/E	0.00	0.00	0.00	0.00	13.15	27.46	16.09	17.84	14.44	26.98
Price to Book	0.00	0.00	0.00	0.00	1.35	0.59	0.73	1.48	1.76	1.95
EV/EBITDA	3.91	2.95	2.24	2.24	6.26	6.50	4.52	6.74	6.93	12.06
Dividend Yield (%)	—	—	—	—	0.40	0.00	0.00	0.00	0.00	0.00

Quarterly Results

Zim Laboratories Ltd.
Brooks Laboratories
Loading...
Medico Remedies
Loading...

In Rs. Cr.	Dec'22	Mar'23	Jun'23	Sep'23	Dec'23	Mar'24	Jun'24	Sep'24	Dec'24	Mar'25
Net Sales	101	105	67.44	85.83	96.29	118	81.82	92.14	96.33	109
Operating Expenses	87.88	89.96	62.61	76.50	84.76	102	73.79	82.61	84.77	94.14
Increase/Decrease in Stock	10.28	4.04	-1.26	-3.08	-10.30	0.59	2.56	3.45	-1.11	-3.64
Raw Material	38.02	44.13	31.74	40.96	51.51	53.49	31.01	35.52	39.88	48.60
Employee Cost	11.80	13.40	12.63	12.83	13.17	14.71	14.51	15.45	14.47	16.32
Selling and Distribution Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Electricity, Power & Fuel Cost	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gen_AdminExpenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Miscellaneous Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Profit	13.09	15.45	4.83	9.32	11.53	15.65	8.04	9.53	11.56	14.60
Other Income	2.40	0.69	1.11	1.42	1.11	1.53	1.00	1.32	1.75	1.71
Interest	1.62	1.27	1.73	1.22	1.70	2.28	2.86	2.89	2.73	2.91
PBDT	13.88	14.88	4.21	9.53	10.95	14.91	6.18	7.96	10.59	13.40
Depreciation and Amortization	3.90	4.93	4.03	4.09	3.94	3.90	4.94	5.00	4.88	5.29
Profit Before Tax	9.98	9.95	0.18	5.44	7.01	11.00	1.23	2.96	5.70	8.11
Tax	3.38	2.71	-0.04	1.29	2.23	2.91	0.34	0.58	1.70	3.22
Profit After Tax	6.60	7.24	0.23	4.15	4.79	8.09	0.90	2.38	4.00	4.88
Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit	6.60	7.24	0.23	4.15	4.79	8.09	0.90	2.38	4.00	4.88
Quarterly Ratios
EPS	1.35	1.49	0.05	0.85	0.98	1.66	0.18	0.49	0.82	1.00
Operating Profit Margin	12.97	14.66	7.16	10.86	11.98	13.28	9.82	10.34	12.00	13.42
Net Profit Margin	6.54	6.87	0.34	4.83	4.97	6.86	1.10	2.58	4.15	4.49

Reverse DCF

Earnings

Discount Rate (%)

Terminal Multiple

5 YEAR

10 YEAR

20 YEAR

49.00%

Implied Growth Rate over a 5 year period*

17.50%

Implied Growth Rate over a 10 year period*

8.00%

Implied Growth Rate over a 20 year period*

*Implied Growth calculated using Newton-Rhapson method.

Learn how to use Reverse DCF

FAQs on Zim Laboratories Ltd. Financials

How strong is Zim Laboratories balance sheet?

Balance sheet of Zim Laboratories is moderately strong, But short term working capital might become an issue for this company.

Is the debt of Zim Laboratories increasing or decreasing?

Yes, The net debt of Zim Laboratories is increasing.
Latest net debt of Zim Laboratories is ₹110 Crs as of Mar-25.
This is greater than Mar-24 when it was ₹85.4 Crs.

Is the profitablity of Zim Laboratories improving?

No, profit is decreasing.
The profit of Zim Laboratories is ₹11.74 Crs for Mar 2025, ₹16.76 Crs for Mar 2024 and ₹25.01 Crs for Mar 2023

Does Zim Laboratories pay decent dividends?

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Zim Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

How has Zim Laboratories allocated its funds?

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress

View FAQ's On Shareholding

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Zim Laboratories Ltd.

Zim Laboratories Ltd.

Has the share price of Zim Laboratories grown faster than its competition?

Is Zim Laboratories stock expensive?

How strong is Zim Laboratories balance sheet?

Is the debt of Zim Laboratories increasing or decreasing?

Is the profitablity of Zim Laboratories improving?

Does Zim Laboratories pay decent dividends?

How has Zim Laboratories allocated its funds?

SIGN UP FOR FREE